Based on @ progression-free survival events , progression-free survival was improved in patients assigned to pembrolizumab @ mg/kg ( HR @ , @ % CI @-@ ; p < @ ) and those assigned to pembrolizumab @ mg/kg ( @ , @-@ ; p < @ ) compared with those assigned to chemotherapy .